JAK2 is a member of the family of non-receptor tyrosine kinases and is a component of the JAK-STAT signal transduction pathway which regulates cell proliferation, differentiation, apoptosis and function of immune system.
JAK2 activating mutation, V617F, is implicated in many myeloproliferative disorders (MPD) like polycythemia vera and essential thrombocythopenia and serves as the diagnostic indicator of MPD. Presence of V617F mutation can be used as an indicator for JAK2 inhibitor therapy.
JAK2-MMD-PCR Mutation Test Kit enables detection of V617F mutation in jak2 gene against a background of wild-type genomic DNA.
The GeneFirst OncoPlex® JAK2 Mutation Test Kit (RUO) is a real-time PCR-based test that detects 617F activating mutation in the human JAK2 gene with high sensitivity. This test is based on the GeneFirst proprietary technology, MMD, which is a combination of specially designed mutation-specific primers, blocker-probe and unique cycling conditions that facilitate selective amplification of multiple mutant alleles – at the same time, blocking amplification from wild type (normal) allele. This allows for the detection of rare mutations against a high background of normal, non-mutated genomic DNA.